Request Demo

Last update 11 Aug 2026

Memantine hydrochloride

Last update 11 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

memantine, Memantine Hydrochloride, Memantine hydrochloride oral dissolving film (Heze Pharmaceutical)

+ [27]

Target

NMDA receptor

Action

antagonists

Mechanism

NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesImmune System Diseases+ [1]

Active Indication

Alzheimer DiseaseDementiaCognitive Dysfunction+ [6]

Inactive Indication

AggressionAgitationAmyotrophic Lateral Sclerosis+ [21]

Originator Organization

Merz Pharma GmbH & Co. KGaA

Active Organization

Libbs Farmacêutica Ltda.Accord Healthcare SL

ratiopharm GmbH

+ [12]

Inactive Organization

Forest Laboratories LLC

Allergan UC

Zhaoqing Xinghu Pharmaceutical Co. Ltd.

+ [8]

License Organization

H. Lundbeck A/S

Daewoong Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Germany (11 Aug 2000),

Dementia

Regulation-

Structure/Sequence

Molecular FormulaC12H22ClN

InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N

CAS Registry41100-52-1

411

Clinical Trials associated with Memantine hydrochloride

NCT07248228

/ RecruitingPhase 2IIT

A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.

Start Date09 Jul 2026

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT07531940

/ Not yet recruitingPhase 1IIT

Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome

Down syndrome (DS) is typically caused by an extra chromosome 21 in the cell nucleus (trisomy 21, or T21). T21 is both the most common cause of genetically defined intellectual disability and the earliest documented cause of Alzheimer's disease (AD)-type pathology. Currently, all presymptomatic individuals with DS are classified as having 'Stage 0' DS-associated AD (DSAD). DSAD pathology evolves inexorably, with virtually all individuals with DS developing AD pathology by age 40, and approximately 50% meeting clinical dementia diagnosis criteria at 55 years of age. This study will test the hypothesis that the FDA-approved AD drug memantine, at higher-than-standard doses, may be effective as a cognitive enhancer in adolescents and young adults with DS. The primary goal of this phase 1b clinical trial will be the assessment of the safety and tolerability of three memantine doses in persons with DS. In addition, we will assess the effect of this drug on cognitive test scores and plasma biomarkers of AD in the study participants. Finally, we will also investigate steady-state plasma levels of memantine and the time course of memantine plasma levels after a single dose in the study participants (pharmacokinetics, or PK). The data generated through this phase 1b study will provide the essential safety, PK, and preliminary efficacy signals required to advance a phase 2 trial evaluating high-dose memantine as a first-in-class therapeutic strategy in DS.

Start Date01 Jun 2026

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

NCT07139834

/ RecruitingPhase 1IIT

Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Start Date01 Jun 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

100 Clinical Results associated with Memantine hydrochloride

100 Translational Medicine associated with Memantine hydrochloride

100 Patents (Medical) associated with Memantine hydrochloride

4,873

Literatures (Medical) associated with Memantine hydrochloride

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Erythrina caffra extract restores memory, modulates cholinergic dysfunction, neuroinflammation, and attenuates oxidative stress in cadmium-induced alzheimer’s disease-like pathology in rats

Article

Author: Ibouzine-Dine, Laila ; El Kourchi, Chaimae ; Didou, Latifa ; Kacimi, Fatima Ezzahra ; Boulbaroud, Samira ; Haddan, Azzouz ; Harhar, Hicham ; Ed-Day, Soumia ; Azzaoui, Fatima-Zahra ; El Gui, Radia

BACKGROUND:

Cadmium (Cd) is a well-established neurotoxic heavy metal. Several epidemiological studies have highlighted its involvement in the pathogenesis of Alzheimer's disease (AD). AD is a multifactorial disorder influenced by environmental factors such as heavy metals. Erythrina caffra (E. caffra) is a medicinal plant rich in bioactive compounds with anti-inflammatory, antioxidant, and anticholinesterase properties. However, its protective potential against Cd-induced neurodegeneration remains insufficiently explored. This study investigated the effects of Cd on memory, cholinergic function, oxidative stress, and neuroinflammation, as key AD-related pathophysiological features, and evaluated the therapeutic potential of E. caffra seeds ethanolic extract.

METHODS AND RESULTS:

AD-like alterations were induced in Wistar rats by intracerebroventricular (ICV) administration of cadmium chloride (CdCl₂). Animals were treated with E. caffra ethanolic extract (2.5 mg/kg) or memantine (20 mg/kg) by oral gavage. Behavioral, neurobiochemical, and histological analyses were performed to assess memory, cholinergic function, oxidative stress, neuroinflammation, and neuronal integrity. Cd exposure significantly impaired memory and disrupted cholinergic function, as evidenced by reduced acetylcholine (ACh) levels in the hippocampus. Moreover, it induced oxidative stress, marked by decreased catalase (CAT), superoxide dismutase (SOD), and non-protein thiols (NPSH), alongside increased proinflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), and hippocampal neuronal loss. Treatment with E. caffra and memantine significantly ameliorated these alterations.

CONCLUSIONS:

E. caffra extract demonstrates neuroprotective effects against Cd-induced AD-like pathology by modulating oxidative stress, neuroinflammation, and cholinergic dysfunction. These findings suggest its potential as a promising therapeutic candidate for mitigating neurodegenerative processes associated with AD.

01 Aug 2026·British Journal of Pharmacology

Memantine prevents acute stress‐induced memory deficits by reversing sex‐dependent pathophysiological glutamatergic alterations in the dorsal hippocampus

Article

Author: Geraci, Federica ; Torrisi, Sebastiano A. ; Amorini, Angela Maria ; D′Ascenzo, Marcello ; Diolosà, Lidia ; Marchetti, Claudia ; Li Volti, Giovanni ; Bellia, Francesco ; Aceto, Giuseppe ; Rizzo, Silvia ; Grasso, Margherita ; Leggio, Gian Marco ; Caraci, Filippo ; Partsinevelos, Konstantinos

Abstract:

Background and Purpose:

The neural mechanisms underlying effects of acute stress on memory are poorly understood. We demonstrated previously that acute stress produces identical spatial memory deficits in male and female mice but through distinct molecular mechanisms, with females exhibiting up‐regulation of N‐methyl‐D‐aspartate (NMDA) receptor subunits in the dorsal hippocampus (dHPC). Here, we tested whether pharmacological manipulation of NMDA receptors prevents stress‐induced memory deficits and hippocampal glutamatergic dysfunction in a sex‐dependent manner.

Experimental Approach:

Male and female mice were exposed to 2 hours of restraint stress. We performed electrophysiological and molecular analysis of the glutamatergic synapse in the dHPC. We evaluated two non‐competitive NMDA receptor antagonists administered pre‐stress: MK‐801, which blocks synaptic and extrasynaptic NMDA receptors, and memantine, which preferentially blocks extrasynaptic NMDA receptors. We evaluated effects of both drugs on stress‐induced spatial memory impairment and the effect of memantine on hippocampal glutamatergic neurotransmission.

Key Results:

Acute stress induces sex‐ and time‐dependent alterations in glutamate–glutamine metabolism, with a striking increase in stressed females. This outcome was associated with female glutamatergic neurotransmission impairment, indicated by reduced miniature EPSC amplitude and AMPA/NMDA ratio at CA3–CA1 synapses. MK‐801 and memantine rescued stress‐induced spatial memory impairment in male and female mice, respectively. Memantine counteracted stress‐induced reduction in AMPA/NMDA ratio in female mice, normalising synaptic strength at CA3–CA1 synapses.

Conclusions and Implications:

Acute stress disrupts hippocampal glutamatergic homeostasis through sex‐dependent pathophysiological mechanisms. The study of sex‐dependent mechanisms may lead to targeted pharmacological treatments for cognitive deficits in stress‐related disorders.

01 Jul 2026·LUMINESCENCE

A Novel Green Spectrofluorimetric Approach for Memantine Quantification With Mechanistic Elucidation Through Quantum Mechanical Modeling and Green Analytical Chemistry Evaluation

Article

Author: Aldhafeeri, Muneef M.

ABSTRACT:

A novel, sustainable spectrofluorimetric method was developed for memantine determination using erythrosin B as a fluorescent probe, addressing critical analytical gaps in pharmaceutical quality control and environmental monitoring. The method exploits static fluorescence quenching through ground‐state complex formation between protonated memantine and anionic erythrosin B. Initially, UV–Vis absorption spectroscopy revealed a significant hypochromic effect accompanied by a hypsochromic shift of 5 nm, with the absorption maximum shifting from 527 to 522 nm upon complex formation, while fluorescence studies demonstrated concentration‐dependent quenching at 527 nm excitation and 553 nm emission wavelengths. Subsequently, temperature‐dependent Stern–Volmer analysis yielded quenching constants decreasing from 6.22 × 10 5 to 4.47 × 10 5 mol L −1 (298–313 K), confirming the static quenching mechanism. Furthermore, Job's method established 2:1 memantine‐to‐erythrosin B stoichiometry, which was validated by quantum mechanical calculations revealing energetically favorable binding interactions. The developed method exhibited excellent analytical performance with a linear range of 0.02–2.0 μg/mL, a detection limit of 6.5 ng/mL, precision (%RSD < 2%), and accuracy (98.59%). Moreover, successful applications included pharmaceutical formulations and spiked environmental water samples, achieving quantitative recoveries ranging from 96% to 104% across different matrices. Finally, a comprehensive sustainability assessment demonstrated superior green credentials compared to conventional chromatographic approaches.

133

News (Medical) associated with Memantine hydrochloride

03 Aug 2026

·www.alphacognition.com

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

Vancouver, BC and Dallas, TX – August 3, 2026 – Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website. Following the release, management will host a conference call to review financial and operating results. Details for the conference call can be found below: Please call the conference telephone number or log on to the web access link five minutes prior to the start time. A replay of the call will be available three hours following the call via the Events section of the Alpha Cognition website. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), an indication for which there are currently no approved treatment options. ZUNVEYL® is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. For further information: LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com Forward-looking Statements This press release contains forward-looking statements within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements are not historical facts and include, but are not limited to, statements regarding the timing of the Company's financial results announcement and conference call, the Company's commercialization activities, business strategy, market opportunities, product development plans, clinical development programs, regulatory activities and future operating performance. Forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on management's current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes it has a reasonable basis for these forward-looking statements, it can give no assurance that such expectations will prove to be correct. Actual results may differ materially from those expressed or implied by these forward-looking statements. Risks and uncertainties that could cause actual results to differ materially include, without limitation, risks related to the commercialization, market acceptance, reimbursement, pricing, distribution and sale of ZUNVEYL®, the Company's ability to maintain and protect its intellectual property, regulatory oversight and product safety matters, manufacturing and supply chain activities, the availability of adequate reimbursement coverage, competition from existing and future therapies, product liability exposure, the outcome of research and development activities, the results of clinical trials, the Company's ability to obtain additional regulatory approvals, and general economic, market and business conditions. Additional information regarding these and other risks and uncertainties is contained in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q, and other filings made with the SEC, as well as the Company's filings with Canadian securities regulatory authorities, each of which is available on the applicable regulatory websites. The forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Drug ApprovalFinancial Statement

29 Jul 2026

·www.biospace.com

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection for benzgalantamine’s pharmaceutical development and potential commercialization into 2042, subject to applicable patent requirements. The European patent may be validated in applicable EPC member states, providing Alpha Cognition with an expanded framework for IP protection across key European markets, including both European Union and non-EU jurisdictions such as Switzerland and the United Kingdom. “This European patent grant is another important step in our strategy to build broad intellectual property protection around benzgalantamine and ZUNVEYL as a differentiated treatment option for patients with mild-to-moderate Alzheimer’s disease,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “By strengthening our IP position in Europe, we are continuing to support the long-term clinical and commercial potential of benzgalantamine.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved by the FDA as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-Looking Statements This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are neither historical facts nor assurances of future performance and are based on the Company's current expectations, estimates, assumptions and projections. Forward-looking statements in this news release include, but are not limited to, statements regarding: the scope, validity, enforceability, geographical coverage, duration and potential commercial value of the Company's intellectual property portfolio relating to benzgalantamine and ZUNVEYL®; the potential validation of the European patent in individual European Patent Convention member states; the ability of the patent to provide intellectual property protection through 2042 or any other period; the Company's intellectual property strategy; the future development, regulatory advancement, commercialization and market acceptance of ZUNVEYL® and benzgalantamine-based products; the potential clinical, commercial and competitive benefits of ZUNVEYL®; and the Company's ability to protect, maintain and expand its intellectual property portfolio. In some cases, forward-looking statements can be identified by the use of words such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "continue," "ongoing," or similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain such words. Although the Company believes it has a reasonable basis for these forward-looking statements, such statements are based on current expectations and assumptions that are subject to significant risks, uncertainties and other factors, many of which are beyond the Company's control. Actual results may differ materially from those expressed or implied by the forward-looking statements as a result of numerous risks and uncertainties, including, without limitation: the Company's ability to obtain sufficient capital to execute its business plans and commercialize ZUNVEYL®; risks relating to the development, regulatory approval, manufacture, distribution, marketing and commercialization of ZUNVEYL® and other product candidates; risks relating to market acceptance, reimbursement and competitive products; risks associated with ongoing regulatory oversight of approved products; risks relating to the scope, validity, enforceability, maintenance, defense and duration of patent rights; risks associated with the validation, protection and enforcement of the European patent in individual jurisdictions; risks that issued patents may be challenged, opposed, invalidated, narrowed, circumvented or otherwise found unenforceable; risks that additional patent applications may not result in issued patents; and other risks described in the Company's filings with the United States Securities and Exchange Commission (the "SEC") and Canadian securities regulatory authorities. No assurance can be given that any patent granted will provide commercially meaningful protection, that any patent will remain valid or enforceable for its full term, that patent rights will provide competitive advantages, or that future patent applications will mature into issued patents. In addition, statements regarding the potential duration of patent protection are based on currently available information and are subject to applicable patent laws, regulatory requirements, maintenance obligations and potential legal challenges. Further information regarding these and other risks can be found under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2026, and in the Company's subsequent filings with the SEC and Canadian securities regulatory authorities. The forward-looking statements contained in this news release are made as of the date hereof and speak only as of such date. Except as required by applicable law, the Company undertakes no obligation to update, revise or otherwise publicly disclose any revisions to any forward-looking statements to reflect events or circumstances occurring after the date of this news release or to reflect the occurrence of unanticipated events. Contacts For further Information: LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

10 Jul 2026

·www.businesswire.com

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET. For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to your institutional representative at B. Riley. There will be no live webcast of the panel discussion. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented acetylcholinesterase inhibitor approved for the treatment of mild-to-moderate Alzheimer's disease in adults. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, including the alpha-7 subtype, which has been studied in preclinical and clinical research. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as a sublingual formulation for Cognitive Impairment with mTBI. Forward-Looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These statements include but are not limited to statements regarding the Company's continued growth and continued commercialization and market adoption of ZUNVEYL, the Company's clinical development plans for benzgalantamine (including in combination with memantine for the treatment of moderate to severe Alzheimer's dementia and as a sublingual formulation for Cognitive Impairment with mTBI), and statements regarding the Company's participation in the B. Riley Securities Mind, Muscle & Vision Summit. In some cases, you can identify forward‐looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risks related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to the development, clinical testing and regulatory approval of the Company's pipeline product candidates, including benzgalantamine in combination with memantine and the sublingual formulation of benzgalantamine for Cognitive Impairment with mTBI, and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at www.sedarplus.ca and the Company's filings with the United States Securities and Exchange Commission (the "SEC"), including those risk factors under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2026 and the Company's other filings with the SEC available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Drug Approval

100 Deals associated with Memantine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04905	Memantine hydrochloride	N06DX01	DB01043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	European Union	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Iceland	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Liechtenstein	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Norway	H. Lundbeck A/S	15 May 2002
Dementia	Germany	H. Lundbeck A/S	11 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia, Vascular	Phase 3	Russia	Merz Pharmaceuticals GmbH	23 Jan 2018
Frontotemporal Dementia	Phase 3	Canada	H. Lundbeck A/S	01 Oct 2007
Multiple Sclerosis, Relapsing-Remitting	Phase 3	France	H. Lundbeck A/S	01 Sep 2005
Amyotrophic Lateral Sclerosis	Phase 3	Portugal	H. Lundbeck A/S	01 Jul 2005
Agitation	Phase 3	United States	Forest Laboratories LLC	01 Sep 2004
Cognitive Dysfunction	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Multiple Sclerosis	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Multiple Sclerosis, Primary Progressive	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Dementia due to Alzheimer's disease (disorder)	Phase 3	Canada	H. Lundbeck A/S	01 Dec 2003
Glaucoma, Open-Angle	Phase 3	-	Allergan UC	01 Mar 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03527472 (ClearMEMory, EULAR2026)	Phase 2	Systemic Lupus Erythematosus	56	Memantine	ykwfsfpcng(pjbxgjlkfz): P-Value = 0.032 View more	Positive	11 Jun 2026
				Placebo
NCT04857983 (CTgov)	Phase 2/3	Schizoaffective disorder \| Schizophrenia	62	Placebo (TCT + PBO)	ayieqnlgsn(fktraqsmhb) = dhlluqiihg bnjwvxxlhh (aowxlnrser, 14.50) View more	-	18 May 2026
				Memantine (TCT + MEM)	ayieqnlgsn(fktraqsmhb) = okrxvfyfmj bnjwvxxlhh (aowxlnrser, 13.13) View more
NCT06501638 (Pubmed \| Circulation)	Phase 2	Atrial Premature Complexes	241	Memantine	qqkapjvojp(czgzxbvswh): Difference (%) = 47.1, P-Value = 0.0045 View more	Positive	21 Apr 2026
				Placebo
NCT05801380 (PHRR230220-0054116, Pubmed \| J Alzheimers Dis Rep)	Not Applicable	Alzheimer Disease	2	MemantineDonepezil + MemantineDonepezil	evydtqimyi(uuwhzkcttl) = vaappvljwa jeapqozcwf (bpklepltlt ) View more	Negative	01 Mar 2026
NCT03703856 (CTgov)	Phase 4	Alzheimer Disease	53	Memantine	ggqhhfjqfv(xdaqpbcydq) = vagtufrnbi kyerdjdyvs (ypgvdhgefv, 8.97) View more	-	07 Jan 2026
NCT01972074 (Pubmed \| JAMA Netw Open)	Phase 2	Autism Spectrum Disorder	42	Memantine	qglycqjmro(gzzairzhwz) = bosftcvfpo jhythqetch (pkjrvjkmvr ) View more	Positive	01 Oct 2025
				Placebo	qglycqjmro(gzzairzhwz) = fnamdkwkny jhythqetch (pkjrvjkmvr ) View more
NCT01535040 (CCCWFU 99311, Pubmed \| Cancer Control)	Phase 2	Smoking Cessation	130	Memantine 10 mg	vnqibvkotj(tgqrzqaqmg) = iqgczbsasb edbdfecykf (ucgckgpuve )	Negative	01 Aug 2025
				Placebo	vnqibvkotj(tgqrzqaqmg) = ezqjszlouk edbdfecykf (ucgckgpuve )
NCT04117178 (MONANTI, CTgov)	Phase 4	Alzheimer Disease \| Dementia due to Parkinson's disease \| Lewy Body Disease	132	Measurement of serum level of anti-dementia drug (Standard of Care)	pbxvgkiouk(mnbanfujbp) = jamffnabtg xotwppnozm (bavffhhbom, 3.19) View more	-	10 Feb 2025
				Measurement of serum level of anti-dementia drug+Memantine+Donepezil (Intervention Arm)	pbxvgkiouk(mnbanfujbp) = rlvyutratj xotwppnozm (bavffhhbom, 3.56) View more
NCT04302870 (MND SMART, Pubmed)	-	Motor Neuron Disease	554	美金刚	ymzahubxah(leyjzgwjdv) = sugyvhtiiu mrmkaqzhft (ydgbwiwhcy )	Negative	19 Sep 2024
				曲唑酮	ymzahubxah(leyjzgwjdv) = zeiolswxpj mrmkaqzhft (ydgbwiwhcy )
NCT04792645 (CTgov)	Phase 2	Trichotillomania \| Skin Diseases	100	Placebo (Placebo)	umxmsiqmeb(lnqlqpcukz) = axrcbukkki cyvgryiubm (zhfsxlxjkf, 2.80) View more	-	01 Aug 2023
				Memantine (Memantine)	umxmsiqmeb(lnqlqpcukz) = buwqriwnbk cyvgryiubm (zhfsxlxjkf, 3.65) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis